Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 13,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer
Interventions: MRI, CESM; Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 30 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: 89Zr-Trastuzumab Human Dosimetry and Safety, HER2 Positive Lesion Detection and Safety; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 938 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2021
U.S. locations: 4
States / cities: Tucson, Arizona • Houston, Texas

Conditions: Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
Interventions: Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 15
States / cities: Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more

Conditions: Hair Thinning
Interventions: Nutrafol Women's Hair Growth Supplemnt, Nutrafol Women's Balance Hair Growth Supplement, Nutrafol Women's Vegan Hair Growth Supplement, Nutrafol Women's Postpartum Hair Growth Supplement, Nutrafol Men's Hair Growth Supplement; Dietary Supplement
Lead sponsor: Nutraceutical Wellness Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Cellulitis
Interventions: teledermatology consult, Routine Care; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Radiation Dermatitis
Interventions: KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview; Drug · Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 12 Years and older
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Psoriasis
Interventions: Med-Jet, Traditional Syringe; Device · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer
Interventions: Olaparib, Pembrolizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Systemic Sclerosis-associated Interstitial Lung Disease
Interventions: Abituzumab 1500 mg, Abituzumab 500 mg, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Melanoma (Skin)
Interventions: ADI-PEG-20, Pharmacology Studies; Biological · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Skin Disease, Cancer, HIV, Diabetes, Chronic Pain
Interventions: Healing HEARTS, Peer Support; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Melanoma
Interventions: glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), glembatumumab vedotin and CDX-301; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more

Conditions: Fasting, Breast Cancer, Survivorship, Breast Cancer Recurrent
Interventions: Fasting; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: M518101, Vehicle; Drug
Lead sponsor: Maruho North America Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Mobile, Alabama • Phoenix, Arizona • San Diego, California + 27 more

Conditions: Breast Cancer, Postoperative Recovery
Interventions: ERAS Protocol, Standard Perioperative Care; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Breast Cancer
Interventions: filgrastim, cyclophosphamide, epirubicin hydrochloride, paclitaxel, adjuvant therapy, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma
Interventions: 4-peptide melanoma vaccine, Ontak; Biological · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Non invasive venous ultrasound; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Blood draw, immunoenzyme technique, biopsy, histopathologic examination; Other · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Inflammation, Skin Inflammation, Aging
Interventions: CeraVe Moisturizing Cream, Vaseline; Other · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 70 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer

DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men

The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Abituzumab in SSc-ILD

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Prolonged Nightly Fasting in Breast Cancer Survivors

Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

ERAS Protocols in Breast Conserving Surgery

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Non-Invasive Imaging for Cording in Breast Cancer Patients

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

Skin Barrier Function and Inflammation in Aging: The BIA Study